An Open-label, Multi-center, Dose-escalation and Expansion, Phase 1/2a Study to Evaluate the Safety, Tolerability, PK/PD, and Preliminary Anti-tumor Activity of GIC-102 Monotherapy in Patients With Advanced Solid Tumors, R/R Non-Hodgkin Lymphoma, and Multiple Myeloma
Latest Information Update: 18 Jul 2024
At a glance
- Drugs GIC-102 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Colorectal cancer; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors GICELL
Most Recent Events
- 09 Jul 2024 Phase has been changed to I\II ,no of patients has been increased ,addition of ORR to the primary endpoinnt
- 09 Jul 2024 Planned number of patients changed from 9 to 50.
- 04 Jun 2024 Results (n=6 as of 31 Dec, 2023)presented at the 60th Annual Meeting of the American Society of Clinical Oncology.